- Home
- AUTL vs VSTM Comparison
AUTL vs VSTM Comparison
Compare AUTL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- VSTM
- Stock Information
- Founded
- AUTL 2014
- VSTM 2010
- Country
- AUTL United Kingdom
- VSTM United States
- Employees
- AUTL N/A
- VSTM N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- VSTM Health Care
- Exchange
- AUTL Nasdaq
- VSTM Nasdaq
- Market Cap
- AUTL 625.4M
- VSTM 598.2M
- IPO Year
- AUTL 2018
- VSTM 2012
- Fundamental
- Price
- AUTL $1.36
- VSTM $9.54
- Analyst Decision
- AUTL Strong Buy
- VSTM Strong Buy
- Analyst Count
- AUTL 5
- VSTM 9
- Target Price
- AUTL $9.12
- VSTM $13.38
- AVG Volume (30 Days)
- AUTL 4.5M
- VSTM 2.6M
- Earning Date
- AUTL 11-11-2025
- VSTM 11-05-2025
- Dividend Yield
- AUTL N/A
- VSTM N/A
- EPS Growth
- AUTL N/A
- VSTM N/A
- EPS
- AUTL N/A
- VSTM N/A
- Revenue
- AUTL $29,934,000.00
- VSTM $2,137,000.00
- Revenue This Year
- AUTL $641.63
- VSTM $88.50
- Revenue Next Year
- AUTL $109.21
- VSTM $398.66
- P/E Ratio
- AUTL N/A
- VSTM N/A
- Revenue Growth
- AUTL 185.17
- VSTM N/A
- 52 Week Low
- AUTL $1.11
- VSTM $2.54
- 52 Week High
- AUTL $5.00
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- AUTL 33.35
- VSTM 57.41
- Support Level
- AUTL $1.26
- VSTM $9.10
- Resistance Level
- AUTL $1.46
- VSTM $10.06
- Average True Range (ATR)
- AUTL 0.09
- VSTM 0.69
- MACD
- AUTL 0.01
- VSTM -0.17
- Stochastic Oscillator
- AUTL 30.49
- VSTM 25.33
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.